Proactiveinvestors USA & Canada Advanced Oncotherapy PLC https://www.proactiveinvestors.com Proactiveinvestors USA & Canada Advanced Oncotherapy PLC RSS feed en Mon, 20 May 2019 05:40:00 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20190517172939_14079128/ Fri, 17 May 2019 12:29:39 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20190517172939_14079128/ <![CDATA[News - Advanced Oncotherapy secures more than £12mln of additional funding ]]> https://www.proactiveinvestors.com/companies/news/220035/advanced-oncotherapy-secures-more-than-12mln-of-additional-funding-220035.html Advanced Oncotherapy PLC (LON:AVO) has secured more than £12mln additional funding to support ongoing work on a next-generation proton beam system.

Credit Suisse has provided £10mln of debt for two years with an annual coupon of 2% above LIBOR (the lending rate between London banks). And additional £2.345mln has come via a share subscription with mainly Swiss institutions taking stock in the group at 40p. That’s a modest discount to Thursday’s closing price.

"The strengthening of our balance sheet during 2018 and early 2019 has placed us in a stronger position to secure additional non-dilutive funding at attractive financial terms,” said chief executive Nicolas Serandour.

Advanced Oncotherapy is developing a state-of-the art, affordable proton beam therapy system called LIGHT.

Technology developed by CERN

The technology is based on work by ADAM, which the company bought in 2013 from CERN, the world’s largest particle physics lab that built the Hadron collider.

The major plus point of proton therapy is that it can pinpoint tumours more precisely, which means less damage to surrounding healthy tissues.

Proton therapy facilities have traditionally been pricey and large, requiring a space the size of a football pitch to run.

But AVO thinks it has solved that problem, and LIGHT is being built to fit in the basement of a townhouse in Harley Street, central London.

Its modular design, lighter weight and better proton efficiency also helps to keep costs down, which should open proton therapy up to many more patients.

"We are moving forward well with our plans to install the first working LIGHT system at the STFC facility at Daresbury, with the integration of additional accelerating modules to allow high energy testing and ultimately regulatory approval," CEO Serandour said.

]]>
Fri, 10 May 2019 08:07:00 -0400 https://www.proactiveinvestors.com/companies/news/220035/advanced-oncotherapy-secures-more-than-12mln-of-additional-funding-220035.html
<![CDATA[RNS press release - Debt facility secured ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20190510070004_14069020/ Fri, 10 May 2019 02:00:04 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20190510070004_14069020/ <![CDATA[News - Advanced Onco gearing up for commercialisation of its LIGHT proton beam therapy system ]]> https://www.proactiveinvestors.com/companies/news/219488/advanced-onco-gearing-up-for-commercialisation-of-its-light-proton-beam-therapy-system-219488.html Advanced Oncotherapy PLC (LON:AVO) is developing a state-of-the art, affordable proton beam therapy system called LIGHT.

The technology is based on work by ADAM, which AVO bought in 2013 from CERN – the world’s largest particle physics lab that built the Hadron collider.

The major plus point of proton therapy is that it can pinpoint tumours more precisely, which means less damage to surrounding healthy tissues.

Proton therapy facilities have traditionally been pricey and large, requiring a space the size of a football pitch to run.

But AVO thinks it has solved that problem, and LIGHT is being built to fit in the basement of a townhouse in Harley Street, central London.

Its modular design, lighter weight and better proton efficiency also helps to keep costs down, which should open proton therapy up to many more patients.

How it’s doing

Building work at the Harley Street facility is expected to finish later this year, with the first patient on track to be treated at the facility in the second half of 2020.

AVO has managed to strike a deal with the freeholder of the building, the Howard de Walden Estate, which is covering the cost of all the construction work.

As the company moves nearer to treating the first patient, it has started to gear up its commercial infrastructure with the appointment of an experienced chief commercial officer.

Moataz Karmalawy is a “veteran in the commercialisation of PBT technology”, according to research house Hardman & Co, given his previous jobs at Varian and Philips Medical.

Financially, the company appears well set after raising more than £12mln in a debt (£10mln) and equity, with much of cash coming out of Switzerland. The debt facility is over two years and carries a coupon of two points over LIBOR.

What bosses are saying

“We are delighted with the progress we have made,” said chief executive Nicolas Serandour, speaking back at the interim results.

“We have strengthened the board with some key changes and we have total confidence in our ability as a team to deliver on our milestones.

“The sub-structural work at the Harley Street facility remains on schedule and we are pleased with the progress at the site.

“We have exciting plans for the future commercialisation of the LIGHT system once completely developed, and our discussions with potential partners around the world are ongoing.”

 

What analysts are saying

“Demand for PBT is increasing worldwide, and the need for a small, flexible, affordable and close-to-patient system is desirable,” said Hardman & Co in a recent note to clients.

“With LIGHT, AVO is aiming to provide customers with a fully integrated PBT solution.

“AVO’s market capitalisation of £78m equates only to the amount of money invested into LIGHT to date, which does not reflect either the enormous technical challenges that have been overcome, or the large market potential.”

Speaking about the appointment of new CCO Moataz Karmalawy, Hardman added: “The appointment of such an experienced executive from a major competitor is a major coup for the company and should provide the market with greater confidence in LIGHTS’s commercial prospects.”

]]>
Wed, 01 May 2019 06:50:00 -0400 https://www.proactiveinvestors.com/companies/news/219488/advanced-onco-gearing-up-for-commercialisation-of-its-light-proton-beam-therapy-system-219488.html
<![CDATA[News - Advanced Oncotherapy appoints a chief commercial officer and president for its US division ]]> https://www.proactiveinvestors.com/companies/news/218660/advanced-oncotherapy-appoints-a-chief-commercial-officer-and-president-for-its-us-division-218660.html Advanced Oncotherapy PLC (LON:AVO) shares jumped higher on Tuesday as the group announced the appointment of Moataz Karmalawy as its chief commercial officer and president of its US division with immediate effect.

The AIM-listed developer of a next-generation proton therapy system for cancer treatment noted that Karmalawy has served as general manager of the Worldwide Particle Therapy Business for Varian Medical Systems Inc., the world's largest manufacturer of radiotherapy equipment for 12 years

READ: Advanced Oncotherapy rises as it obtains international quality standard for LIGHT system

The group pointed out that, whilst at Varian Medical, Karmalawy integrated the acquired proton therapy business into the division, before growing the order book to in excess of US$1bn and achieving a 50% market share of the global particle therapy products market.

Before joining Varian Medical, Karmalawy worked at Philips Medical Systems Inc. for 10 years where he served in several senior executive roles, it added.

Commenting on his appointment, Karmalawy, said: "Advanced Oncotherapy stands out as an incredibly exciting opportunity within the proton therapy market. The global capacity to treat patients with proton therapy has been disappointingly low due to the high cost of traditional proton therapy technologies. 

"As a result, only 1% of patients eligible for radiotherapy are being treated with proton therapy. Advanced Oncotherapy's technology will make this treatment more affordable and accessible to cancer patients worldwide and the LIGHT system has a number of technical advantages to existing technology that will deliver better patient outcomes and offer an accuracy and adjustability beyond legacy technologies."

Advanced Oncotherapy pointed out that his appointment is a non-board appointment.

In afternoon trading, shares in Advanced Oncotherapy were 10% higher at 43.50p.

 -- Adds share price -- 

]]>
Tue, 16 Apr 2019 08:09:00 -0400 https://www.proactiveinvestors.com/companies/news/218660/advanced-oncotherapy-appoints-a-chief-commercial-officer-and-president-for-its-us-division-218660.html
<![CDATA[RNS press release - Senior Management Appointment ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20190416070003_14042017/ Tue, 16 Apr 2019 02:00:03 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20190416070003_14042017/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20190307090042_13993830/ Thu, 07 Mar 2019 04:00:42 -0500 https://www.proactiveinvestors.com/companies/rns/4119/LSE20190307090042_13993830/ <![CDATA[RNS press release - Grant of options ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20190222070005_13978052/ Fri, 22 Feb 2019 02:00:05 -0500 https://www.proactiveinvestors.com/companies/rns/4119/LSE20190222070005_13978052/ <![CDATA[RNS press release - Appointment of Nominated Adviser and Joint Broker ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20190201070003_13954558/ Fri, 01 Feb 2019 02:00:03 -0500 https://www.proactiveinvestors.com/companies/rns/4119/LSE20190201070003_13954558/ <![CDATA[RNS press release - Schedule 2(g) Disclosure ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20190130114528_13952103/ Wed, 30 Jan 2019 06:45:28 -0500 https://www.proactiveinvestors.com/companies/rns/4119/LSE20190130114528_13952103/ <![CDATA[RNS press release - Total Voting Rights and Significant Shareholdings ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20190129093804_13950203/ Tue, 29 Jan 2019 04:38:04 -0500 https://www.proactiveinvestors.com/companies/rns/4119/LSE20190129093804_13950203/ <![CDATA[RNS press release - Schedule 2(g) Disclosure ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20190124121422_13945885/ Thu, 24 Jan 2019 07:14:22 -0500 https://www.proactiveinvestors.com/companies/rns/4119/LSE20190124121422_13945885/ <![CDATA[RNS press release - Result of General Meeting ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20190122152910_13943080/ Tue, 22 Jan 2019 10:29:10 -0500 https://www.proactiveinvestors.com/companies/rns/4119/LSE20190122152910_13943080/ <![CDATA[News - Advanced Oncotherapy rises as it obtains international quality standard for LIGHT system ]]> https://www.proactiveinvestors.com/companies/news/212944/advanced-oncotherapy-rises-as-it-obtains-international-quality-standard-for-light-system-212944.html Advanced Oncotherapy PLC (LON:AVO) shares rose in mid-morning trading Monday after it received a quality standard certification for its LIGHT proton therapy system following an audit by compliance firm Lloyd’s Register.

ISO 13485:2016 is an internationally recognised quality standard that ensures the consistent design, development, production, installation and sale of medical devices that are safe for their intended purposes.

READ: Advanced Oncotherapy raises £10mln at a premium

The company said the certification was an important milestone that would allow it to continue developing its LIGHT system in compliance with the highest safety and product performance standards.

It would also allow it to make the product available for patient treatment once the medical device file had been approved.

The LIGHT system is focused on the use of protons, small sub-atomic particles, to treat tumour growths in patients using an accelerator beam similar to that of linear x-rays currently used in cancer treatment.

AVO is currently focused on increasing the power of the LIGHT proton beam to 230 mega-electron volts, the level required to treat deep-seated tumours in patients.

Dr Michel Baelen, the company’s director of regulatory affairs, said the compliance with the quality standard illustrated the importance the firm placed on the quality of its product, as well as “dedication to ensuring that the infrastructure to develop and manufacture our product is safe, effective and reliable”.

AVO shares were up 1.3% at 39p.

--Adds share price--

]]>
Mon, 21 Jan 2019 08:09:00 -0500 https://www.proactiveinvestors.com/companies/news/212944/advanced-oncotherapy-rises-as-it-obtains-international-quality-standard-for-light-system-212944.html
<![CDATA[RNS press release - ISO 13485:2016 certification for medical devices ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20190121070006_13940423/ Mon, 21 Jan 2019 02:00:06 -0500 https://www.proactiveinvestors.com/companies/rns/4119/LSE20190121070006_13940423/ <![CDATA[News - Advanced Oncotherapy raises £10mln at a premium ]]> https://www.proactiveinvestors.com/companies/news/211633/advanced-oncotherapy-raises-10mln-at-a-premium-211633.html Advanced Oncotherapy PLC (LON:AVO) is raising £10.0mln as it presses ahead with the building of its next-generation LIGHT proton therapy system on Harley Street.

Investors taking part in the fundraising, including Paris-based DNCA Investments, are paying 40p a share – an 11% premium to Thursday’s closing price.

READ: AVO improves performance of LIGHT system

As well as funding the continued development of the first LIGHT system, the money will also pay for software development and costs relating to the new testing and assembly site being set up at a science park in Cheshire.

In its last stock exchange announcement in October, AVO announced it had doubled the power of the proton beam in the LIGHT system.

]]>
Fri, 21 Dec 2018 07:37:00 -0500 https://www.proactiveinvestors.com/companies/news/211633/advanced-oncotherapy-raises-10mln-at-a-premium-211633.html
<![CDATA[RNS press release - Launch of 2018 SAYE Scheme ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20181221101519_13913120/ Fri, 21 Dec 2018 05:15:19 -0500 https://www.proactiveinvestors.com/companies/rns/4119/LSE20181221101519_13913120/ <![CDATA[RNS press release - Proposed Direct Subscription to raise £10.0m ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20181221070002_13912358/ Fri, 21 Dec 2018 02:00:02 -0500 https://www.proactiveinvestors.com/companies/rns/4119/LSE20181221070002_13912358/ <![CDATA[News - Advanced Oncotherapy’s LIGHT system has “fast head start” on changing cancer treatment market, says broker goetzpartners ]]> https://www.proactiveinvestors.com/companies/news/206801/advanced-oncotherapys-light-system-has-fast-head-start-on-changing-cancer-treatment-market-says-broker-goetzpartners-206801.html Advanced Oncotherapy PLC (LON:AVO), which is developing a breakthrough new proton therapy system for cancer sufferers, could have a “fast head-start” in the race to replace other forms of treatment in the market, according to analysts at broker goetzpartners.

In a note to clients, the broker said that the company’s proton beam treatment system, known as Linac Image Guided Hadron Technology (LIGHT), could help it take “the entire growth” from its cyclotron competitors, a technology that will become obsolete by the end of 2023.

Cyclotron technology involves lengthy and complicated building preparation, with heavy cyclotrons and large concrete bunkers make the installation a major building project, which is, regardless of pricing, often a big hurdle.

However, the broker says the LIGHT system, which is “faster and less complicated combined with a cheaper production process”, could give the company a step up against both cyclotrons and more conventional LINAC (linear accelerator) systems.

The proton therapy industry, in which AVO operates, offers “significant structural growth”, goetz said, with its own numbers forecasting a US$8bn market by the end of 2030.

LIGHT tech backed by world-leading physicists

AVO’s beam technology is currently being worked on by the team at ADAM, a spin-off from renowned Swiss physics lab CERN, which includes some of the world leading physicists.

The firm recently announced that it had successfully integrated the four sections of its LIGHT proton accelerator, the proton source, the Radiofrequency Quadrupole (RFQ), four Side Coupled Drift Tube Linacs (SCDTLs), and two high-energy accelerating structures, the Coupled Cavity Linacs (CCLs), at the lab and had achieved an energy of 52 mega-electron volts (MeV), double the amount needed to treat superficial cancer tumours.

READ: Advanced Oncotherapy rockets as it improves performance of LIGHT cancer treatment system

However, the company isn’t stopping and is aiming to add 13 more CCL modules which would increase the energy level to 230MeV, the level required to treat deep-seated tumours.

goetzpartners expects the company to achieve this energy level in 2019, adding that they saw “limited” risks to the set up of the company’s LIGHT system for its first customer at a clinic in Harley Street, the renowned private medical district in London.

First player in ‘holistic’ oncology process

AVO’s partnership with Swedish radiotherapy software firm, RaySearch, also gives it a potential first-mover advantage in developing “a fully integrated and holistic oncology treatment process”, says goetz.

The broker says that the combination of the LIGHT system and RaySearch’s treatment planning and oncology information systems would go “far beyond an optimal use of proton therapy systems”.

goetzpartners has Advanced Oncotherapy pegged with an ‘Outperform’ rating and a price target of 155p, a premium of over 255% on its current share price of 43.5p.

With a current market cap of £55.9mln, the broker is targeting a potential value of around £143mln.

]]>
Wed, 10 Oct 2018 09:00:00 -0400 https://www.proactiveinvestors.com/companies/news/206801/advanced-oncotherapys-light-system-has-fast-head-start-on-changing-cancer-treatment-market-says-broker-goetzpartners-206801.html
<![CDATA[News - Advanced Oncotherapy rockets as it improves performance of LIGHT cancer treatment system ]]> https://www.proactiveinvestors.com/companies/news/206754/advanced-oncotherapy-rockets-as-it-improves-performance-of-light-cancer-treatment-system-206754.html Advanced Oncotherapy PLC (LON:AVO) shares shot up in late-morning trading Wednesday after the firm doubled the power of its LIGHT proton beam cancer treatment system.

The firm said that it had successfully integrated the four sections of its LIGHT proton accelerator, the proton source, the Radiofrequency Quadrupole (RFQ), four Side Coupled Drift Tube Linacs (SCDTLs), and two high-energy accelerating structures, the Coupled Cavity Linacs (CCLs), at its testing facility at CERN in Geneva.

READ: Advanced Oncotherapy now in a solid position, says research house

As a result, AVO said the proton beam had now been accelerated through these units to the anticipated energy of 52 mega-electron volts (MeV), double the output energy needed to treat superficial tumours which it reached at the end of last month.

The firm said it was now focused on adding 13 more CCL modules which would increase the energy level to 230MeV, the level required to treat deep-seated tumours.

Meanwhile, the company also said that RaySearch AB, a leading software firm for radio and particle therapies, would be providing their ‘RayCare’ oncology information system (OIS) to both its Harley Street treatment site and its assembly site at Daresbury Laboratory for integration.

AVO had also partnered with Tel-Aviv based firm P-Cure to provide an advanced robotic treatment chair and a vertically tracking diagnostic CT scanner, which would be received at AVO’s assembly centre in 2019.

READ: Advanced Oncotherapy passes key technological milestone

The company also said the construction of its Harley Street site remained on track and was expected to conclude by the middle of next year, while work was progressing at its assembly site to build and prepare the test facility ready for the installation of the full LIGHT system from later this year.

Nicolas Sérandour, chief executive of Advanced Oncotherapy, said the firm had “already achieved the most challenging aspect of constructing a new linear accelerator”, with the addition of the additional CCLs “a relatively simple process”.

He added that discussions with potential customers were “multiplying” and that expected to accelerate as the next phase of development was reached.

Shares were up 30.3% at 43p.

--Adds share price--

]]>
Wed, 10 Oct 2018 08:06:00 -0400 https://www.proactiveinvestors.com/companies/news/206754/advanced-oncotherapy-rockets-as-it-improves-performance-of-light-cancer-treatment-system-206754.html
<![CDATA[RNS press release - GPSL Research - Flash Note on AVO ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20181010073052_13822983/ Wed, 10 Oct 2018 02:30:52 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20181010073052_13822983/ <![CDATA[RNS press release - Technological update ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20181010070003_13822495/ Wed, 10 Oct 2018 02:00:03 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20181010070003_13822495/ <![CDATA[RNS press release - GPSL Research - Flash Note on AVO ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20181004110713_13816703/ Thu, 04 Oct 2018 06:07:13 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20181004110713_13816703/ <![CDATA[News - Advanced Oncotherapy now in a solid position, says research house ]]> https://www.proactiveinvestors.com/companies/news/206187/advanced-oncotherapy-now-in-a-solid-position-says-research-house-206187.html Advanced Oncotherapy PLC’s (LON:AVO) interim results revealed the business had turned a corner, according to research issued by Goetz Partners Securities.

It is now in a solid position financially following the completion of a £40mln financing round that ended the share overhang from its debt-equity facilities.

Cash and equivalents at June 30 were £3.32mln, though this figure excluded £6.41mln raised from investors and a £2.92mln tax credit, which occurred early in the second half.

“The company has managed a major turnaround of its dire financial situation from last year,” Goetz said.

New device LIGHT years ahead?

AVO is developing a proton beam system that blasts cancer called LIGHT. The initials stand for Linac Image Guided Hadron Technology. The company’s kit is cheaper and smaller than the current units, which are almost prohibitively expensive.

It has the ability to propel protons at the speeds generated by much larger machines.

The proton accelerator used by Advanced Oncotherapy was licensed from CERN, the European Organisation for Nuclear Research, which is currently hunting the ‘God particle’.

Last Thursday, investors were told the company’s LIGHT system had passed a major technological milestone with the unit generating proton beams energetic enough to treat superficial tumours.

Commercial traction 

Commercially AVO’s technology is gaining traction. It has inked a distribution agreement with Liquid Harmony for China and other parts of Asia, while discussions are ongoing for sites in the US, Europe, Asia and the Middle East.

Goetz believes the group’s LIGHT technology has a greater potential than next-generation PT cyclotrons cancer killers to replace a significant share of photon linacs currently on the market.

“We feel that cyclotron manufactures have seen their peak a couple of years ago with a limited chance of recovery,” the research house said.

“The replacement power from LIGHT is based on technical superiority, price and easy installment.”

]]>
Tue, 02 Oct 2018 12:04:00 -0400 https://www.proactiveinvestors.com/companies/news/206187/advanced-oncotherapy-now-in-a-solid-position-says-research-house-206187.html
<![CDATA[RNS press release - Half-year Report ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180928070008_13808010/ Fri, 28 Sep 2018 02:00:08 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180928070008_13808010/ <![CDATA[News - Advanced Oncotherapy passes key technological milestone ]]> https://www.proactiveinvestors.com/companies/news/205817/advanced-oncotherapy-passes-key-technological-milestone-205817.html Advanced Oncotherapy PLC (LON:AVO) said it has passed a key technological milestone on schedule.

Researchers at the CERN facility in Geneva working on the company’s LIGHT system have confirmed it is now generating proton beams with sufficient energy to treat superficial tumours.

“This announcement marks the shift from a complex ‑ albeit well-proven ‑ scientific and physics reality into a medical application with tangible and direct implications for patients,” said chief executive Nicolas Sérandour.

“This very important step supports the confidence we have in delivering our plan and being in a position to offer a system that delivers a better outcome for patients whilst generating more value for the operators."

The results from the work to date showed the LIGHT proton beam technology comfortably treated simulated superficial tumours and marginally deeper cancers.

Healthy tissue, such as the eye and the lens, was spared because of the targeted nature of the device. Dosing was well controlled.

Next target in sight 

The development team is now focused on the “relatively low-execution risk activity” of adding further accelerating modules.

This will ensure the AVO equipment can treat all indications suitable for proton therapy.

“A further technical update will be provided in the next few days,” the company said.

LIGHT stands for Linac Image Guided Hadron Technology. The AVO kit is cheaper and smaller than the current units, which are almost prohibitively expensive.

It has the ability to propel protons at the speeds generated by much larger machines.

The proton accelerator used by Advanced Oncotherapy was licensed from CERN, the European Organisation for Nuclear Research, which is currently hunting the ‘God particle’.

]]>
Thu, 27 Sep 2018 07:24:00 -0400 https://www.proactiveinvestors.com/companies/news/205817/advanced-oncotherapy-passes-key-technological-milestone-205817.html
<![CDATA[RNS press release - Technological update ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180927070008_13806196/ Thu, 27 Sep 2018 02:00:08 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180927070008_13806196/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180910113257_13784901/ Mon, 10 Sep 2018 06:32:57 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180910113257_13784901/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180907115239_13783256/ Fri, 07 Sep 2018 06:52:39 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180907115239_13783256/ <![CDATA[RNS press release - Completion of the £6.41m Placing ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180903113850_13776657/ Mon, 03 Sep 2018 06:38:50 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180903113850_13776657/ <![CDATA[RNS press release - Director Declaration ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180828070010_13768799/ Tue, 28 Aug 2018 02:00:10 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180828070010_13768799/ <![CDATA[RNS press release - Exercise of Warrants and Issue of Shares ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180809070004_13748962/ Thu, 09 Aug 2018 02:00:04 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180809070004_13748962/ <![CDATA[News - Advanced Oncotherapy pulls in £6.4mln from Swiss investors ]]> https://www.proactiveinvestors.com/companies/news/202069/advanced-oncotherapy-pulls-in-64mln-from-swiss-investors-202069.html Advanced Oncotherapy PLC (LON:AVO), the developer of proton beam systems used to treat cancer, has completed a share placing with Swiss investors that brought in £6.41mln.

Shares were issued at 49p each, which was a modest discount to last night’s closing price of 51p, with a number of prominent private banks and healthcare providers buying into the company.

READ: Advanced Oncotherapy on track with development of its LIGHT system

The cash injection from the fundraise, which was organised by Geneva-based Synergy Wealth Management, will be used for “general working capital purposes” as the company continues to develop its LIGHT proton beam system.

LIGHT stands for Linac Image Guided Hadron Technology. The AVO kit is cheaper and smaller than the current units, which are almost prohibitively expensive.

It has the ability to propel protons at the speeds generated by much larger machines.

The proton accelerator used by Advanced Oncotherapy was licensed from CERN, the European Organisation for Nuclear Research, which is currently hunting the ‘God particle’.

Shares well bid

The shares, which were 16.5p a year ago, are currently changing hands for 53.5p each, up 5%.

Today, the business is worth £87mln, reflecting the progress that has been made in recent months.

In June, it told investors that work to develop the first centre for the LIGHT system, on London’s Harley Street, was progressing to plan.

The first patients are expected to be treated in the second half of 2020. AVO is also in discussions for a second site in Birmingham and is assessing a number of potential sites in the US, Europe, Asia and the Middle East.

]]>
Thu, 02 Aug 2018 07:20:00 -0400 https://www.proactiveinvestors.com/companies/news/202069/advanced-oncotherapy-pulls-in-64mln-from-swiss-investors-202069.html
<![CDATA[RNS press release - £6.41m Placing ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180802070017_13740643/ Thu, 02 Aug 2018 02:00:17 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180802070017_13740643/ <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180725153442_13731388/ Wed, 25 Jul 2018 10:34:42 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180725153442_13731388/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180704164042_13706059/ Wed, 04 Jul 2018 11:40:42 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180704164042_13706059/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180704163521_13706044/ Wed, 04 Jul 2018 11:35:21 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180704163521_13706044/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180704110522_13705437/ Wed, 04 Jul 2018 06:05:22 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180704110522_13705437/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180704110029_13705401/ Wed, 04 Jul 2018 06:00:29 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180704110029_13705401/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180704090550_13705148/ Wed, 04 Jul 2018 04:05:50 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180704090550_13705148/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180704090018_13705140/ Wed, 04 Jul 2018 04:00:18 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180704090018_13705140/ <![CDATA[RNS press release - Directorate Changes ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180702070006_13700590/ Mon, 02 Jul 2018 02:00:06 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180702070006_13700590/ <![CDATA[RNS press release - Final Results ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180627070004_13694836/ Wed, 27 Jun 2018 02:00:04 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180627070004_13694836/ <![CDATA[RNS press release - Update on financing ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180531070003_13660677/ Thu, 31 May 2018 02:00:03 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180531070003_13660677/ <![CDATA[RNS press release - Technological update ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180529070013_13657062/ Tue, 29 May 2018 02:00:13 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180529070013_13657062/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180511163519_13638682/ Fri, 11 May 2018 11:35:19 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180511163519_13638682/ <![CDATA[RNS press release - Update on Distribution Agreement Payment ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180511070004_13637215/ Fri, 11 May 2018 02:00:04 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180511070004_13637215/ <![CDATA[RNS press release - UK assembly and testing site agreement ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180508070008_13631759/ Tue, 08 May 2018 02:00:08 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180508070008_13631759/ <![CDATA[RNS press release - GPSL Research on Advanced Oncotherapy Plc ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180426135052_13620336/ Thu, 26 Apr 2018 08:50:52 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180426135052_13620336/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/4119/LSE20180405070004_13592372/ Thu, 05 Apr 2018 02:00:04 -0400 https://www.proactiveinvestors.com/companies/rns/4119/LSE20180405070004_13592372/